Nama's AI scorecard currently rates Taysha Gene Therapies Sell (2.3 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

When does TSHA report earnings?

Taysha Gene Therapies's next scheduled report is on Nov 11, 2026. Analysts expect EPS of -$0.12.

What is the TSHA price target?

The median analyst price target from 13 analysts is $12.00, with a range of $9.00 – $19.00.

Is TSHA Shariah compliant?

Nama's AAOIFI-style screen reads Taysha Gene Therapies as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

Taysha Gene Therapies (TSHA)

Healthcare · Biotechnology · NASDAQ

Taysha Gene Therapies (TSHA) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $1.41B and a free-cash-flow yield of -6.7%. Over the most recent reported fiscal year, revenue grew 17.3%. Nama's AI scorecard rates it Sell, 2.3 out of 10. On 12-month momentum it ranks in the middle band of its market.

AI scorecard

Sell · 2.3/10

Clearly negative, short of the bottom band. As of Nov 7, 2026.

Momentum

Middle · +13.0% over 12 months ex. last

Middle fifth of its market on the past year's move.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-73.1%

How far the last close sits under the highest price of the past five years.

Market cap	$1.41B
Trailing P/E	—
Price / book	3.6
Price / sales	216.5
FCF yield	-6.7%
Dividend yield	—
Gross margin	100.0%
Operating margin	-2792.3%
Net margin	0.0%
Revenue growth (YoY)	+17.3%
Revenue growth (3-yr annual)	+57.5%
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	1.2
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

TSHA earnings

Next report: Nov 11, 2026 (Q3 2026, EPS estimate -$0.12). Beat the EPS estimate in 1 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q2 2026	Aug 11, 2026	-$0.13	-$0.11	-18.2%	$0
Q1 2026	May 6, 2026	-$0.11	-$0.10	-10.0%	$0
Q4 2025	Mar 19, 2026	-$0.07	-$0.10	+30.0%	$5.49M
Q3 2025	Nov 4, 2025	-$0.09	-$0.09	+0.0%	$0

TSHA analyst price target

Median target $12.00 from 13 analysts, ranging $9.00 – $19.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9

Explore live TSHA data on Nama Insights →

TSHA FAQ

Is TSHA a buy?: Nama's AI scorecard currently rates Taysha Gene Therapies Sell (2.3 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does TSHA report earnings?: Taysha Gene Therapies's next scheduled report is on Nov 11, 2026. Analysts expect EPS of -$0.12.
What is the TSHA price target?: The median analyst price target from 13 analysts is $12.00, with a range of $9.00 – $19.00.
Is TSHA Shariah compliant?: Nama's AAOIFI-style screen reads Taysha Gene Therapies as Not Shariah Compliant. At least one of the three ratios or the industry test failed.